Condition: Hypercholesterolemia · Hypertriglyceridemia · Refractory Hyperlipidemia · Sponsor: Verve Therapeutics, Inc.
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Clinical Study Center | Clearwater, Florida, United States | Recruiting |
| Clinical Study Center | Miami Lakes, Florida, United States | Recruiting |
| Clinical Study Center | Port Orange, Florida, United States | Recruiting |
| Clinical Study Center | New York, New York, United States | Recruiting |
| Clinical Study Center | Adelaide, Australia | Recruiting |
| Clinical Study Center | Melbourne, Australia | Recruiting |
| Clinical Study Center | Chicoutimi, Canada | Recruiting |
| Clinical Study Center | Montreal, Canada | Recruiting |
| Clinical Study Center | Toronto, Canada | Recruiting |
| Clinical Study Center | Amsterdam, Netherlands | Recruiting |
| Clinical Study Center | Cape Town, South Africa | Recruiting |
| Clinical Study Center | Johannesburg, South Africa | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06451770